{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T01:21:08Z","timestamp":1793496068156,"version":"4.5.0"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,12,1]],"date-time":"2017-12-01T00:00:00Z","timestamp":1512086400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100005075","name":"University Medical Center Groningen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005075","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001721","name":"University of Groningen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001721","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Mosapharma","award":["662616"],"award-info":[{"award-number":["662616"]}]},{"DOI":"10.13039\/501100005075","name":"University Medical Center Groningen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005075","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001721","name":"University of Groningen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001721","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","prd-journal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Parkinsonism &amp; Related Disorders"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1016\/j.parkreldis.2017.09.025","type":"journal-article","created":{"date-parts":[[2017,9,29]],"date-time":"2017-09-29T21:45:19Z","timestamp":1506721519000},"page":"33-38","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":49,"special_numbering":"C","title":["Continuous subcutaneous apomorphine infusion in Parkinson's disease patients with cognitive dysfunction: A retrospective long-term follow-up study"],"prefix":"10.1016","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6531-7955","authenticated-orcid":false,"given":"Robbert W.K.","family":"Borgemeester","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teus","family":"van Laar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.parkreldis.2017.09.025_bib1","first-page":"137","article-title":"Pharmacokinetics of apomorphine in Parkinson's disease","volume":"45","author":"Gancher","year":"1995","journal-title":"J.\u00a0Neural Transm. Suppl."},{"key":"10.1016\/j.parkreldis.2017.09.025_bib2","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1002\/1531-8257(200009)15:5<789::AID-MDS1005>3.0.CO;2-H","article-title":"Apomorphine: an underutilized therapy for Parkinson's disease","volume":"15","author":"Poewe","year":"2000","journal-title":"Mov. Disord."},{"key":"10.1016\/j.parkreldis.2017.09.025_bib3","doi-asserted-by":"crossref","first-page":"271","DOI":"10.2217\/nmt.14.17","article-title":"Clinical insights into use of apomorphine in Parkinson's disease: tools for clinicians","volume":"4","author":"Henriksen","year":"2014","journal-title":"Neurodegener. Dis. Manag."},{"key":"10.1016\/j.parkreldis.2017.09.025_bib4","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1586\/14737175.2013.839235","article-title":"Subcutaneous infusions of apomorphine: a reappraisal of its therapeutic efficacy in advanced Parkinson's disease","volume":"13","author":"Grandas","year":"2013","journal-title":"Expert Rev. Neurother."},{"key":"10.1016\/j.parkreldis.2017.09.025_bib5","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1586\/14737175.2014.928202","article-title":"The role of subcutaneous infusion of apomorphine in Parkinson's disease","volume":"14","author":"Wenzel","year":"2014","journal-title":"Expert Rev. Neurother."},{"key":"10.1016\/j.parkreldis.2017.09.025_bib6","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/j.parkreldis.2015.06.012","article-title":"Expert consensus group report on the use of apomorphine in the treatment of Parkinson's disease: clinical practice recommendations","volume":"21","author":"Trenkwalder","year":"2015","journal-title":"Park. Relat. Disord."},{"key":"10.1016\/j.parkreldis.2017.09.025_bib7","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.parkreldis.2015.11.013","article-title":"Motor and non-motor outcomes of continuous apomorphine infusion in 125 Parkinson's disease patients","volume":"23","author":"Borgemeester","year":"2016","journal-title":"Park. Relat. Disord."},{"key":"10.1016\/j.parkreldis.2017.09.025_bib8","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1002\/mds.22063","article-title":"Efficacy of long-term continuous subcutaneous apomorphine infusion in advanced Parkinson's disease with motor fluctuations: a multicenter study","volume":"23","author":"Garc\u00eda Ruiz","year":"2008","journal-title":"Mov. Disord."},{"key":"10.1016\/j.parkreldis.2017.09.025_bib9","first-page":"1111","article-title":"Quality of life in Parkinson's disease improved by apomorphine pump: the OPTIPUMP cohort study","volume":"263","author":"Drapier","year":"2016","journal-title":"J.\u00a0Neurol."},{"key":"10.1016\/j.parkreldis.2017.09.025_bib10","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.archger.2004.04.039","article-title":"Continuous apomorphine infusion (CAI) and neuropsychiatric disorders in patients with advanced Parkinson's disease: a follow-up of two years","volume":"9","author":"Morgante","year":"2004","journal-title":"Arch. Gerontol. Geriatr. Suppl."},{"key":"10.1016\/j.parkreldis.2017.09.025_bib11","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.parkreldis.2011.08.010","article-title":"Apomorphine infusion in advanced Parkinson's patients with subthalamic stimulation contraindications","volume":"18","author":"Drapier","year":"2012","journal-title":"Park. Relat. Disord."},{"key":"10.1016\/j.parkreldis.2017.09.025_bib12","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1002\/mds.20237","article-title":"Comparative cognitive effects of bilateral subthalamic stimulation and subcutaneous continuous infusion of apomorphine in Parkinson's disease","volume":"19","author":"Alegret","year":"2004","journal-title":"Mov. Disord."},{"key":"10.1016\/j.parkreldis.2017.09.025_bib13","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1136\/jnnp.2005.078659","article-title":"Clinical and neuropsychological follow up at 12 months in patients with complicated Parkinson's disease treated with subcutaneous apomorphine infusion or deep brain stimulation of the subthalamic nucleus","volume":"77","author":"De Gaspari","year":"2006","journal-title":"J.\u00a0Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.parkreldis.2017.09.025_bib14","first-page":"579","article-title":"5-year prospective assessment of advanced Parkinson disease patients treated with subcutaneous apomorphine infusion or deep brain stimulation","volume":"258","author":"Antonini","year":"2011","journal-title":"J.\u00a0Neurol."},{"key":"10.1016\/j.parkreldis.2017.09.025_bib15","first-page":"197","article-title":"Chronic subcutaneous infusion therapy with apomorphine in advanced Parkinson's disease compared to conventional therapy: a real life study of non motor effect","volume":"1","author":"Martinez-Martin","year":"2011","journal-title":"J.\u00a0Park. Dis."},{"key":"10.1016\/j.parkreldis.2017.09.025_bib16","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1002\/mds.26067","article-title":"EuroInf: a multicenter comparative observational study of apomorphine and levodopa infusion in Parkinson's disease","volume":"30","author":"Martinez-Martin","year":"2015","journal-title":"Mov. Disord."},{"key":"10.1016\/j.parkreldis.2017.09.025_bib17","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.parkreldis.2009.05.006","article-title":"Continuous subcutaneous infusion of apomorphine can be used safely in patients with Parkinson's disease and pre-existing visual hallucinations","volume":"16","author":"van Laar","year":"2010","journal-title":"Park. Relat. Disord."},{"key":"10.1016\/j.parkreldis.2017.09.025_bib18","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1136\/jnnp.55.3.181","article-title":"Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases","volume":"55","author":"Hughes","year":"1992","journal-title":"J.\u00a0Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.parkreldis.2017.09.025_bib19","doi-asserted-by":"crossref","first-page":"2314","DOI":"10.1002\/mds.21844","article-title":"Diagnostic procedures for Parkinson's disease dementia: recommendations from the movement disorder society task force","volume":"22","author":"Dubois","year":"2007","journal-title":"Mov. Disord."},{"key":"10.1016\/j.parkreldis.2017.09.025_bib20","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.parkreldis.2012.02.010","article-title":"Sensitivity and specificity of addenbrooke's cognitive examination, mattis dementia rating scale, frontal assessment battery and mini mental state examination for diagnosing dementia in Parkinson's disease","volume":"18","author":"Kasz\u00e1s","year":"2012","journal-title":"Park. Relat. Disord."},{"key":"10.1016\/j.parkreldis.2017.09.025_bib21","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1002\/mds.23750","article-title":"SCOPA-cognition cutoff value for detection of Parkinson's disease dementia","volume":"26","author":"Verbaan","year":"2011","journal-title":"Mov. Disord."},{"key":"10.1016\/j.parkreldis.2017.09.025_bib22","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1002\/gps.1759","article-title":"Cholinesterase inhibitors in dementia with Lewy bodies\u2014a comparative analysis","volume":"22","author":"Bhasin","year":"2007","journal-title":"Int. J. Geriatr. Psychiatry"},{"key":"10.1016\/j.parkreldis.2017.09.025_bib23","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s10286-011-0119-5","article-title":"Consensus statement on the definition of orthostatic hypotension, neurally mediated syncope and the postural tachycardia syndrome","volume":"21","author":"Freeman","year":"2011","journal-title":"Clin. Auton. Res."},{"key":"10.1016\/j.parkreldis.2017.09.025_bib24","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.parkreldis.2011.10.016","article-title":"Body mass index in Parkinson's disease: a meta-analysis","volume":"18","author":"van der Marck","year":"2012","journal-title":"Park. Relat. Disord."},{"key":"10.1016\/j.parkreldis.2017.09.025_bib25","doi-asserted-by":"crossref","first-page":"2649","DOI":"10.1002\/mds.23429","article-title":"Systematic review of levodopa dose equivalency reporting in Parkinson's disease","volume":"25","author":"Tomlinson","year":"2010","journal-title":"Mov. Disord."},{"key":"10.1016\/j.parkreldis.2017.09.025_bib26","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","article-title":"Controlling the false discovery rate: a practical and powerful approach to multiple testing","volume":"57","author":"Benjamini","year":"1995","journal-title":"J.\u00a0R. Stat. Soc. Ser. B"},{"key":"10.1016\/j.parkreldis.2017.09.025_bib27","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1111\/jgs.12027","article-title":"Motor profile and drug treatment of nursing home residents with Parkinson's disease","volume":"60","author":"Weerkamp","year":"2012","journal-title":"J.\u00a0Am. Geriatr. Soc."},{"key":"10.1016\/j.parkreldis.2017.09.025_bib28","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.parkreldis.2016.09.001","article-title":"Medication use in people with late stage Parkinson's disease and parkinsonism living at home and in institutional care in north-east England: a balance of symptoms and side-effects?","volume":"32","author":"Hand","year":"2016","journal-title":"Park. Relat. Disord."},{"key":"10.1016\/j.parkreldis.2017.09.025_bib29","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1212\/WNL.0000000000003213","article-title":"Loss of independence in early Parkinson disease: a 5-year population-based incident cohort study","volume":"87","author":"Bjornestad","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/j.parkreldis.2017.09.025_bib30","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1002\/mds.20837","article-title":"Predictors of weight loss in Parkinson's disease","volume":"21","author":"Uc","year":"2006","journal-title":"Mov. Disord."}],"container-title":["Parkinsonism &amp; Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1353802017303577?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1353802017303577?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,27]],"date-time":"2024-06-27T11:38:30Z","timestamp":1719488310000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1353802017303577"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12]]},"references-count":30,"alternative-id":["S1353802017303577"],"URL":"https:\/\/doi.org\/10.1016\/j.parkreldis.2017.09.025","relation":{},"ISSN":["1353-8020"],"issn-type":[{"value":"1353-8020","type":"print"}],"subject":[],"published":{"date-parts":[[2017,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Continuous subcutaneous apomorphine infusion in Parkinson's disease patients with cognitive dysfunction: A retrospective long-term follow-up study","name":"articletitle","label":"Article Title"},{"value":"Parkinsonism & Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.parkreldis.2017.09.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}